How Intuitive Surgical Makes its Money: Revenue Breakdown
A breakdown of Intuitive Surgical (ISRG) financials. See how Intuitive Surgical makes money from Instruments & Accessories, Systems, Services, and more using their 2024 annual report.
How Does Intuitive Surgical Make its Money?
Intuitive Surgical is the pioneer and dominant player in robotic-assisted surgery, best known for its da Vinci surgical systems. The company’s robots are used in over 10 million surgical procedures ranging from prostatectomies to hernia repairs. Intuitive employs a razor-and-blade business model — placing expensive surgical systems in hospitals, then generating recurring revenue from instruments, accessories, and services every time the systems are used. The company launched its next-generation da Vinci 5 system in 2024.
Intuitive Surgical’s competitive moat is formidable. It has a 20+ year head start in robotic surgery, an installed base of over 9,000 da Vinci systems worldwide, and an ecosystem of 70,000+ trained surgeons. Each surgeon who learns on a da Vinci system represents years of fellowship-level training — they are unlikely to switch to a competitor’s platform. Hospitals with installed da Vinci systems have invested $1-2 million per unit, built robotic-surgery operating rooms, and restructured surgical workflows around the platform. This combination of surgeon training lock-in, hospital capital commitment, and clinical outcome data creates switching costs that no competitor has overcome despite decades of trying.
Intuitive Surgical (ISRG) Business Model
Intuitive Surgical Competitors
Intuitive Surgical’s key competitors and comparable public companies in the medical devices sector include Stryker, Johnson & Johnson, and Abbott Laboratories. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Intuitive Surgical stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Instruments & Accessories | $4,700 | $4,100 | +14.6% |
| Systems | $2,100 | $1,700 | +23.5% |
| Services | $1,100 | $1,000 | +10.0% |
| Operating Leases | $500 | $450 | +11.1% |
| Total Revenue | $8,400 | $7,100 | +18.3% |
Instruments & Accessories — 56% of Revenue
The razor blade in Intuitive’s razor-and-blade model. Every da Vinci procedure requires single-use or limited-use instruments (EndoWrist instruments designed to mimic human wrist motion) and accessories (cannulas, trocars, energy instruments, stapling devices). Each instrument has a programmed use limit — typically 10 uses — after which the instrument must be replaced, ensuring predictable recurring revenue tied directly to procedure volume. Revenue surged 14.6% in 2024, driven by both a growing installed base of systems and increasing procedure volumes per system.
This segment is the most important because it converts the one-time system sale into decades of recurring consumable revenue. A single da Vinci system generates an estimated $1,500-2,000 in instrument and accessory revenue per procedure, and hospitals perform hundreds of procedures per system annually. As new procedure categories adopt robotic surgery (general surgery, thoracic, colorectal), instrument revenue per installed system grows.
Systems — 25% of Revenue
Revenue from the sale and placement of da Vinci surgical systems (da Vinci Xi, X, SP, and the new da Vinci 5) and the newer Ion bronchoscopic system for lung biopsy. Revenue surged 23.5% in 2024, driven by the launch of da Vinci 5, which prompted both first-time purchases and upgrades from existing customers. A new da Vinci 5 system costs approximately $2.3 million (up from ~$1.5-1.8M for the Xi), and hospitals justify the investment through procedure volume, surgeon recruitment, and reduced post-surgical complications (shorter hospital stays).
The da Vinci 5 launch is a generational upgrade: it adds force feedback (allowing surgeons to “feel” tissue resistance for the first time), improved 3D visualization, a more ergonomic surgeon console, and Intuitive’s cloud-based analytics platform. The upgrade cycle could drive several years of elevated system revenue as the global installed base transitions from Xi/X to the da Vinci 5.
Services — 13% of Revenue
Annual service contracts for maintaining da Vinci systems, including preventive maintenance, field service, and software updates. Revenue grew 10.0% in 2024, largely tracking the growth of the installed system base. Service revenue is highly predictable — virtually all hospitals with da Vinci systems purchase annual service contracts, typically costing $150,000-200,000 per system per year. Service is high-margin, recurring, and grows automatically as the installed base expands.
Operating Leases — 6% of Revenue
Revenue from da Vinci systems placed under operating lease agreements rather than outright purchase. Some hospitals, particularly community hospitals or international customers, prefer leasing to reduce upfront capital outlay. Revenue grew 11.1% in 2024. Operating leases lower the barrier to adoption for smaller facilities and convert to recurring revenue over the lease term, after which the customer typically purchases a new system outright.
Intuitive Surgical (ISRG) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $8,400 | $7,100 |
| Cost of Revenue | $2,800 | $2,400 |
| Gross Profit | $5,600 | $4,700 |
| Operating Expenses | $2,700 | $2,300 |
| Operating Income | $2,900 | $2,400 |
| Net Income | $2,300 | $1,800 |
All values in millions USD unless otherwise stated.
Financial data sourced from Intuitive Surgical SEC Filings.
Intuitive Surgical (ISRG) Key Financial Metrics
- Gross Margin: 66.7%
- Operating Margin: 34.5%
- Revenue Growth: 18.3%
Is Intuitive Surgical Profitable?
Yes, Intuitive Surgical is highly profitable with margins that reflect the premium economics of a medical device platform leader. The 66.7% gross margin is exceptional — driven by the high-margin instruments & accessories segment where consumable costs are a fraction of the $1,500-2,000 per-procedure price. The 34.5% operating margin reflects strong conversion of gross profit despite significant R&D spending (~13% of revenue) required to maintain the technology lead and develop next-generation platforms. Net income surged 27.8% to $2.3 billion on 18.3% revenue growth, demonstrating meaningful operating leverage as the company scales. The razor-and-blade model means profitability naturally improves over time: each system placed generates years of high-margin instrument consumption and service contracts, and the installed base has been compounding for two decades.
Intuitive Surgical (ISRG): What to Watch
- Da Vinci 5 adoption and upgrade cycle — The launch of da Vinci 5 is the most important near-term catalyst. The pace of new placements and upgrades from the existing installed base (9,000+ Xi/X systems) will drive multi-year system revenue growth.
- Procedure growth in general surgery — While urology (prostatectomy) was the first robotic-surgery procedure, general surgery (hernia repair, cholecystectomy, colorectal) represents a much larger addressable market. Procedure mix shifting toward general surgery is critical for long-term volume growth.
- Ion lung biopsy platform expansion — The Ion system for robotic-assisted bronchoscopy targeting lung nodule biopsy is Intuitive’s second platform. Early adoption has been strong, and lung cancer screening expansion could drive significant procedure growth.
- Competitive entry from Medtronic Hugo and J&J OTTAVA — Medtronic’s Hugo system is gaining regulatory approvals globally, and J&J’s OTTAVA platform is in development. While neither can match Intuitive’s installed base or surgeon training ecosystem, competitive pressure could impact system pricing and market share in international markets.
- International installed base growth — The US accounts for ~70% of the installed base, and international markets (Europe, Asia, Latin America) are significantly underpenetrated. Expanding robotic surgery adoption in hospitals outside the US is a key long-term growth vector.
Intuitive Surgical (ISRG) Financial Summary
Intuitive Surgical is the undisputed leader in robotic-assisted surgery with 9,000+ installed da Vinci systems and 70,000+ trained surgeons worldwide. Revenue grew 18.3% to $8.4 billion in 2024, supercharged by the da Vinci 5 launch (Systems +23.5%) and continued procedure growth driving Instruments & Accessories (+14.6%). The 66.7% gross margin and 34.5% operating margin reflect the exceptional razor-and-blade economics where one-time system placements generate decades of recurring consumable revenue. Net income surged 27.8% to $2.3 billion. The growth story is about expanding the addressable procedure market — moving robotic surgery from urology and gynecology into general surgery, thoracic surgery, and lung biopsy (Ion platform) — while the da Vinci 5 upgrade cycle provides a multi-year system revenue tailwind.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.